Ofatumumab
- PMID: 20068404
- PMCID: PMC2726602
- DOI: 10.4161/mabs.1.4.8895
Ofatumumab
Abstract
Ofatumumab is an anti-CD20 IgG1kappa human monoclonal antibody that is being considered by the US Food and Drug Administration and the European Medicines Agency for marketing approval as a treatment for chronic lymphocytic leukemia. The mAb is also being studied as a treatment for lymphoma, rheumatoid arthritis and multiple sclerosis. The candidate targets the same antigen as rituximab, but ofatumumab binds a novel, membrane-proximal epitope, and dissociates from its target at a slower rate compared to rituximab. Ofatumumab might be approved in the US by August 2009.
References
-
- Alexander DD, Mink PJ, Adami HO, Chang ET, Cole P, Mandel JS, et al. The non-Hodgkin lymphomas: A review of the epidemiologic literature. Int J Cancer. 2007;120:1–39. - PubMed
-
- Cavenagh JD, Lister TA. Chronic lymphocyte leukemia. Diagnosis and management. In: Schiller GJ, editor. Chronic Leukemias and Lymphomas. Biology, Pathophysiology and Clinical Management. Totova, New Jersey: Humana Press Inc.; 2003. pp. 23–53.
-
- Nikbin B, Bonab MM, Khosravi F, Talebian F. Role of B cells in pathogenesis of multiple sclerosis. Int Rev Neurobiol. 2007;79:13–42. - PubMed
-
- Waaler E. On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. Acta Pathol Microbiol Scand. 1940;17:172–188. - PubMed
-
- Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical